SFP
CRSP icon

Sterling Financial Planning’s CRISPR Therapeutics CRSP Stock Holding History

Sterling Financial Planning’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-106
Closed -$12K – 162
2021
Q3 		$12K Hold
106
– – 0.01% 300
2021
Q2 		$17K Hold
106
– – 0.01% 263
2021
Q1 		$13K Hold
106
– – 0.01% 252
2020
Q4 		$16K Buy
+106
New +$12.5K 0.01% 231

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sterling Financial Planning's CRSP Position: Q4 2021 in Review

Sterling Financial Planning sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 106 shares — an estimated $12K sold.

Sterling Financial Planning first reported a position in CRSP in Q4 2020 and held it in 4 quarters. The position peaked at $17K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Sterling Financial Planning reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sterling Financial Planning sold 106 CRISPR Therapeutics shares in Q4 2021, an estimated $12K.
  • Sterling Financial Planning first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 4 quarters.
  • Sterling Financial Planning's CRISPR Therapeutics position peaked at $17K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Sterling Financial Planning's 13F filing for Q4 2021, filed 2 Feb 2022.